Imperial Capital Starts Spirit Airlines (SAVE) at Outperform
Get Alerts SAVE Hot Sheet
Rating Summary:
4 Buy, 14 Hold, 7 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
Imperial Capital initiates coverage on Spirit Airlines (NASDAQ: SAVE) with a Outperform rating and a price target of $51.00, suggesting 22% upside.
Analyst Michael Derchin commented, "While SAVE has a successful ultra-low cost model, with among the highest pretax margins in the industry on a consistent basis, the stock has declined over 50% from its December 2014 highs. The primary reason for the weakness in its shares, in our view, is investor concerns regarding the domestic competitive environment. Over the past two years, the Big 3 (American Airlines [AAL], Delta Air Lines [DAL], and United Airlines [UAL]), as well as Southwest Airlines (LUV), matched SAVE's ultra-low cost carrier fares more aggressively than in previous years."
The analyst added, "We attribute the increased competition to three factors: 1) lower jet fuel prices, which increased marginal capacity, 2) the sunset of the Wright Amendment, which increased long haul capacity from Dallas Love Field and 3) a greater focus on attracting domestic leisure customers, as domestic and international business travel demand weakened. Concerns about SAVE's competitive position are over-done, in our view, as evidenced by its superior pretax margins despite increased competition. In fact, we believe SAVE’s recent competitive experience is not dissimilar to those faced by LUV and Ryanair (RYAAY) during the early stages of their growth plans, which turned out to be tremendous buying opportunities at the time."
For an analyst ratings summary and ratings history on Spirit Airlines click here. For more ratings news on Spirit Airlines click here.
Shares of Spirit Airlines closed at $41.88 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TD Cowen Starts Grindr (GRND) at Buy
- Safran SA (SAF:FP) (SAFRY) PT Raised to EUR211 at Citi, 'remain positive on the aftermarket'
- 4D Molecular Therapeutics (FDMT) PT Lowered to $63 at BMO Capital, 'uncertainty remains a lingering overhang until the PhIII readout'
Create E-mail Alert Related Categories
Analyst Comments, New CoverageRelated Entities
Imperial CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!